Telix Pharmaceuticals Limited (ASX: TLX) announced on Wednesday that it has entered an exclusive distribution agreement with Wiik Pharma ApS for its prostate cancer imaging agent, Illuccix (TLX591-CDx), in Denmark, Finland, Norway and Sweden.

Wiik Pharma, a Danish nuclear medicine specialist, will hold exclusive commercial distribution rights for a three-year period from each country's national approval date.

In 2020, the Nordic region reported 27,000 new prostate cancer cases, surpassing lung and bowel cancer incidences. Wiik Pharma, established in 2015, is a Danish pharma company focusing on nuclear medicine and radiopharmaceuticals.

Telix, headquartered in Melbourne, Australia, with global operations, concentrates on diagnostic and therapeutic radiopharmaceuticals. Its lead product, gallium-68 gozetotide, has FDA, TGA, and Health Canada approvals, with ongoing applications in the UK, EU and Brazil.